Trial Profile
Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms VALERIA
- 09 Jul 2019 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 New trial record